BioSpace News Archive

Policy

Right-To-Try Drug Bill Defeated in House

Federal right-to-try legislation that would have allowed terminally ill patients access to experimental therapies without approval from the U.S. Food and Drug Administration failed to muster enough support in the U.S. House of Representatives.

March 14, 2018
·
3 min read
·
Alex Keown
Drug Development

PharmaJet Releases Positive Phase I Results for Hantavirus Vaccines

PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS).

March 14, 2018
·
3 min read
·
Mark Terry
Genetown

Foghorn Therapeutics Launches with $50 Million

Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.

March 14, 2018
·
2 min read
·
Mark Terry
Drug Development

Auris Medical Fails Again in Phase III Trial

Auris Medical has gone down swinging again in attempting to develop a treatment for tinnitus after it announced its Phase III trial failed to meet endpoints.

March 14, 2018
·
2 min read
·
Alex Keown
Drug Development

8 Biotech Companies with Upcoming Catalysts

Here’s a look at eight biopharma companies with upcoming catalysts.

March 14, 2018
·
3 min read
·
Mark Terry
Biotech Beach

Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding

Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals has secured $63.5 million in Series B financing.

March 14, 2018
·
2 min read
·
Alex Keown
Policy

Theranos’ Elizabeth Holmes Charged with Fraud

Elizabeth Holmes, the founder of embattled biotech Theranos, and former company president Sunny Balwani have been charged with massive fraud by the U.S. Securities and Exchange Commission.

March 14, 2018
·
3 min read
·
Alex Keown
Business

Zymeworks Reports 2017 Year-End Financial Results

Zymeworks Inc. reported financial results for the year ended December 31, 2017.

March 14, 2018
·
3 min read
Business

Quanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017

Quanterix Corporation reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously announced in January 2018.

March 14, 2018
·
4 min read
WallachBeth Capital, LLC Acts as the Sole Placement Agent for SmartZyme’s Ongoing Series B-1 Offering

WallachBeth Capital, a leading provider of institutional execution services, is acting as the sole placement agent for SmartZyme BioPharma’s Series B-1 preferred-stock round.

March 14, 2018
·
1 min read